Evidence map›Paper›PMID 32519795›Full record

ArticleDiabetes, obesity & metabolism2020

The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.

Shweta Urva, Tamer Coskun, Corina Loghin, Xuewei Cui, Emily Beebe, Libbey O'Farrell, Daniel A Briere, Charles Benson, Michael A Nauck, Axel Haupt

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 3 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 3 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Shweta UrvaEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.ORCID 0000-0002-3681-479X
Tamer CoskunEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Corina LoghinEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Xuewei CuiEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Emily BeebeEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Libbey O'FarrellEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Daniel A BriereEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Charles BensonEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Michael A NauckDiabetes Division, Katholisches Klinikum Bochum, St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany.ORCID 0000-0002-5749-6954
Axel HauptEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.ORCID 0000-0003-4502-0470
Eli Lilly (United States) · USSt. Josef-Hospital · DE

Funding

Funding was provided by Eli Lilly and Company
6 · The paper itself

Abstract

The effect of dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide on gastric emptying (GE) was compared to that of GLP-1RAs in non-clinical and clinical studies. GE was assessed following acute and chronic treatment with tirzepatide in diet-induced obese mice versus semaglutide or long-acting GIP analogue alone. Participants [with and without type 2 diabetes (T2DM)] from a phase 1, 4-week multiple dose study received tirzepatide, dulaglutide or placebo. GE was assessed by acetaminophen absorption. In mice, tirzepatide delayed GE to a similar degree to that achieved with semaglutide; however, these acute inhibitory effects were abolished after 2 weeks of treatment. GIP analogue alone had no effect on GE or on GLP-1's effect on GE. In participants with and without T2DM, once-weekly tirzepatide (≥5 and ≥4.5 mg, respectively) delayed GE after a single dose. This effect diminished after multiple doses of tirzepatide or dulaglutide in healthy participants. In participants with T2DM treated with an escalation schedule of tirzepatide 5/5/10/10 or 5/5/10/15 mg, a residual GE delay was still observed after multiple doses. These data suggest that tirzepatide's activity on GE is comparable to that of selective GLP-1RAs.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 ReceptorAnimalsBlood GlucoseGastric EmptyingGastric Inhibitory PolypeptideGlucagon-Like Peptide 1GlucoseMiceTirzepatideBlood GlucoseGastric Inhibitory PolypeptideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucoseTirzepatideantidiabetic drugGIPGLP-1 analogueincretin therapytype 2 diabetes

Identifiers

PMID32519795
PMCPMC7539915
OpenAlexW3034133160

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.